Innate Pharma (IPHYF) Short Interest Ratio & Short Volume

Short interest is the volume of Innate Pharma shares that have been sold short but have not yet been covered or closed out. As of March 31st, investors have sold 2,100 shares of IPHYF short. 0.00% of Innate Pharma's shares are currently sold short. Learn More on Innate Pharma's current short interest.

The short interest ratio, also known as the "days to cover ratio", is calculated by dividing the number of shares of a stock sold short divided by its average trading volume. A short interest ratio ranging between 1 and 4 generally indicates strong positive sentiment about a stock and a lack of short sellers. A short interest ratio of 10 or greater indicates strong pessimism about a stock. IPHYF shares currently have a short interest ratio of 21.0. Learn More on Innate Pharma's short interest ratio.

Companies that have a short interest as a percentage of float below 10% indicates positive investor sentiment and few short sellers. Stocks with a short interest percentage above 10% is considered high, suggesting some investors are pessimistic about the stock. Companies with a short interest percentage of 20% or more indicates widespread negative sentiment. 0.00% of Innate Pharma's floating shares are currently sold short.

Innate Pharma saw a increase in short interest during the month of March. As of March 31st, there was short interest totaling 2,100 shares, an increase of 133.3% from the previous total of 900 shares. Changes in short volume can be used to identify positive and negative investor sentiment. Investors that short sell a stock are betting that its price will decline in the future. An increase in short sale volume suggests bearish (negative) sentiment among investors. A decrease on short sale volume suggests bullish (positive) sentiment.

0.00% of Innate Pharma's shares are currently sold short. Here is how the short interest of companies in the industry of "biological products, except diagnostic" compare to Innate Pharma: Ginkgo Bioworks Holdings, Inc. (30.83%), Cullinan Therapeutics, Inc. (24.05%), Relay Therapeutics, Inc. (11.28%), MeiraGTx Holdings plc (2.68%), Tourmaline Bio, Inc. (20.14%), Autolus Therapeutics plc (5.01%), Sana Biotechnology, Inc. (32.16%), Tectonic Therapeutic (10.28%), REGENXBIO Inc. (12.13%), Allogene Therapeutics, Inc. (24.91%),

As of the most recent reporting period, the following stocks had the largest short interest positions: Invesco QQQ ($21.93 billion), iShares 20+ Year Treasury Bond ETF ($9.31 billion), Strategy Incorporated ($8.42 billion), Charter Communications, Inc. ($4.52 billion), Apollo Global Management, Inc. ($4.26 billion), Super Micro Computer, Inc. ($3.98 billion), Capital One Financial Co. ($3.79 billion), TC Energy Co. ($3.43 billion), AppLovin Co. ($2.91 billion), and Schlumberger Limited ($2.89 billion). View all of the most shorted stocks.

Short selling IPHYF is an investing strategy that aims to generate trading profit from Innate Pharma as its price is falling. To short a stock, an investor borrows shares, sells them and buys the shares back on the public market later to return it to the lender. Short sellers are betting that a stock will decline in price. If the stock does drop after selling, the short seller buys it back at a lower price and returns it to the lender. The difference between the sell price and the buy price is the trader's profit.

A short squeeze for Innate Pharma occurs when it has a large amount of short interest and its stock increases in price. This forces short sellers to cover their short interest positions by buying actual shares of IPHYF, which in turn drives the price of the stock up even further.

Short interest is typically published by a stock exchange once per month. However, NASDAQ publishes a report for U.S. stocks, including IPHYF, twice per month. The most recent reporting period available is March, 31 2025.